Debrisoquine	debrisoquine	S_chemicals	O
phenotype	phenotype	O	O
and	and	O	O
the	the	O	O
pharmacokinetics	pharmacokinetics	O	O
and	and	O	O
beta-2	beta-2	S_chemicals	O
receptor	receptor	O	O
pharmacodynamics	pharmacodynamics	O	O
of	of	O	O
metoprolol	metoprolol	O	O
and	and	O	O
its	its	O	O
enantiomers	enantiomers	O	O
.	.	O	O

The	the	O	O
metabolism	metabolism	O	O
of	of	O	O
the	the	O	O
cardioselective	cardioselective	O	O
beta-blocker	beta-blocker	O	O
metoprolol	metoprolol	O	O
is	is	O	O
under	under	O	O
genetic	genetic	O	O
control	control	O	O
of	of	O	O
the	the	O	O
debrisoquine/sparteine	debrisoquine/sparteine	O	O
type	type	O	O
.	.	O	O

The	the	O	O
two	two	O	O
metabolic	metabolic	O	O
phenotypes	phenotypes	O	O
,	,	O	O
extensive	extensive	O	O
(	(	O	O
EM	em	O	O
)	)	O	O
and	and	O	O
poor	poor	O	O
metabolizers	metabolizers	O	O
(	(	O	O
PM	pm	O	O
)	)	O	O
,	,	O	O
show	show	O	O
different	different	O	O
stereoselective	stereoselective	O	O
metabolism	metabolism	O	O
,	,	O	O
resulting	resulting	O	O
in	in	O	O
apparently	apparently	O	O
higher	higher	O	O
beta-1	beta-1	S_chemicals	O
adrenoceptor	adrenoceptor	S_chemicals	O
antagonistic	antagonistic	O	O
potency	potency	O	O
of	of	O	O
racemic	racemic	S_chemicals	O
metoprolol	metoprolol	O	O
in	in	O	O
EMs	ems	O	O
.	.	O	O

We	we	O	O
investigated	investigated	O	O
if	if	O	O
the	the	O	O
latter	latter	O	O
also	also	O	O
applies	applies	O	O
to	to	O	O
the	the	O	O
beta-2	beta-2	S_chemicals	O
adrenoceptor	adrenoceptor	S_chemicals	O
antagonism	antagonism	O	O
by	by	O	O
metoprolol	metoprolol	O	O
.	.	O	O

The	the	O	O
drug	drug	S_chemicals	O
effect	effect	O	O
studied	studied	O	O
was	was	O	O
the	the	O	O
antagonism	antagonism	O	O
by	by	O	O
metoprolol	metoprolol	O	O
of	of	O	O
terbutaline-induced	terbutaline-induced	O	O
hypokalemia	hypokalemia	O	S_disease
.	.	O	O

By	by	O	O
using	using	O	O
pharmacokinetic	pharmacokinetic	O	O
pharmacodynamic	pharmacodynamic	O	O
modeling	modeling	O	O
the	the	O	O
pharmacodynamics	pharmacodynamics	O	O
of	of	O	O
racemic	racemic	S_chemicals	O
metoprolol	metoprolol	O	O
and	and	O	O
the	the	O	O
active	active	O	O
S-isomer	s-isomer	S_chemicals	O
,	,	O	O
were	were	O	O
quantitated	quantitated	O	O
in	in	O	O
EMs	ems	O	O
and	and	O	O
PMs	pms	O	O
in	in	O	O
terms	terms	O	O
of	of	O	O
IC50	ic50	O	O
values	values	O	O
,	,	O	O
representing	representing	O	O
metoprolol	metoprolol	O	O
plasma	plasma	O	O
concentrations	concentrations	O	O
resulting	resulting	O	O
in	in	O	O
half-maximum	half-maximum	O	O
receptor	receptor	O	O
occupancy	occupancy	O	O
.	.	O	O

Six	six	O	O
EMs	ems	O	O
received	received	O	O
0.5	0.5	O	O
mg	mg	O	O
of	of	O	O
terbutaline	terbutaline	O	O
s.c	s.c	O	O
.	.	O	O
on	on	O	O
two	two	O	O
different	different	O	O
occasions	occasions	O	O
:	:	O	O
1	1	O	O
)	)	O	O
1	1	O	O
hr	hr	O	O
after	after	O	O
administration	administration	O	O
of	of	O	O
a	a	O	O
placebo	placebo	O	O
and	and	O	O
2	2	O	O
)	)	O	O
1	1	O	O
hr	hr	O	O
after	after	O	O
150	150	O	O
mg	mg	O	O
of	of	O	O
metoprolol	metoprolol	O	O
p.o	p.o	O	O
.	.	O	O

Five	five	O	O
PMs	pms	O	O
were	were	O	O
studied	studied	O	O
according	according	O	O
to	to	O	O
the	the	O	O
same	same	O	O
protocol	protocol	O	O
,	,	O	O
except	except	O	O
for	for	O	O
a	a	O	O
higher	higher	O	O
terbutaline	terbutaline	O	O
dose	dose	O	O
(	(	O	O
0.75	0.75	O	O
mg	mg	O	O
)	)	O	O
on	on	O	O
day	day	O	O
2	2	O	O
.	.	O	O

Blood	blood	O	O
samples	samples	O	O
for	for	O	O
the	the	O	O
analysis	analysis	O	O
of	of	O	O
plasma	plasma	O	O
potassium	potassium	O	O
,	,	O	O
terbutaline	terbutaline	O	O
,	,	O	O
metoprolol	metoprolol	O	O
(	(	O	O
racemic	racemic	S_chemicals	O
,	,	O	O
R-	r-	O	O
and	and	O	O
S-isomer	s-isomer	S_chemicals	O
)	)	O	O
,	,	O	O
and	and	O	O
alpha-hydroxymetoprolol	alpha-hydroxymetoprolol	O	O
concentrations	concentrations	O	O
were	were	O	O
taken	taken	O	O
at	at	O	O
regular	regular	O	O
time	time	O	O
intervals	intervals	O	O
,	,	O	O
during	during	O	O
8	8	O	O
hr	hr	O	O
after	after	O	O
metoprolol	metoprolol	O	O
.	.	O	O

In	in	O	O
PMs	pms	O	O
,	,	O	O
metoprolol	metoprolol	O	O
increased	increased	O	O
the	the	O	O
terbutaline	terbutaline	O	O
area	area	O	O
under	under	O	O
the	the	O	O
plasma	plasma	O	O
concentration	concentration	O	O
vs.	vs.	O	O
time	time	O	O
curve	curve	O	O
(	(	B_chemicals	O
+	+	I_chemicals	O
67	67	O	O
%	%	O	O
)	)	O	O
.	.	O	O

Higher	higher	O	O
metoprolol/alpha-hydroxymetoprolol	metoprolol/alpha-hydroxymetoprolol	O	O
ratios	ratios	O	O
in	in	O	O
PMs	pms	O	O
were	were	O	O
predictive	predictive	O	O
for	for	O	O
higher	higher	O	O
R-/S-isomer	r-/s-isomer	O	O
ratios	ratios	O	O
of	of	O	O
unchanged	unchanged	O	O
drug	drug	S_chemicals	O
.	.	O	O

There	there	O	O
was	was	O	O
a	a	O	O
difference	difference	O	O
in	in	O	O
metoprolol	metoprolol	O	O
potency	potency	O	O
with	with	O	O
higher	higher	O	O
racemic	racemic	S_chemicals	O
metoprolol	metoprolol	O	O
IC50	ic50	O	O
values	values	O	O
in	in	O	O
PMs	pms	O	O
(	(	O	O
72	72	O	O
+	+	O	O
/-	/-	O	O
7	7	O	O
ng.ml-1	ng.ml-1	O	O
)	)	O	O
than	than	O	O
EMs	ems	O	O
(	(	O	O
42	42	O	O
+	+	O	O
/-	/-	O	O
8	8	O	O
ng.ml-1	ng.ml-1	O	O
,	,	O	O
P	p	O	O
less	less	O	O
than	than	O	O
.001).(ABSTRACT	.001).(abstract	O	O
TRUNCATED	truncated	O	O
AT	at	O	O
250	250	O	O
WORDS	words	O	O
)	)	O	O

